Recombinant Mouse IGF-I (carrier-free) 10 µg
Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
Points clés
Mouse IGF-I is a member of the IGF family that is comprised of three members: IGF-I, IGF-II, and insulin. IGF-I and IGF-II share approximately 50% similarity with insulin at the amino acid level. Mouse IGF-I is synthesized as a 165 amino acid pre-pro-IGF-I, which includes the signal peptide, the mature protein, and the C-terminal E-peptide; the pro-IGFI possesses a proprotein convertase/furin cleavage site preceding the E-peptide. Pro-IGF-I is processed to the mature, active protein, and this procedure requires glucose regulating protein 94 (GRP94) that possesses chaperone activity towards IGF-I. Deletion of muscle GRP94 impairs muscle and body growth by inhibiting local production of IGF proteins. Seven binding proteins have been described (IGFBP-1 to 7). IGFBPs extend the half life and regulate the availability of IGF-I and IGF-II. It has been described that IGFBP3 is the main circulating binding protein for IGF's; in serum, approximately 75% of circulating IGF-I and IGF-II bind to IGFBP3 and the co-carrier acid labile subunit (ALS). IGF-I binds to three receptors, and the binding to IGFIR promotes cell proliferation, survival, differentiation, and migration. IGF-I is a key factor for muscle growth and repair. Inactivation of IGF-RI in skeletal muscle leads to 10-30% lower mass and delayed regeneration after injury.;
Garantie
Garantie 0 Mois
Description
Mouse IGF-I is a member of the IGF family that is comprised of three members: IGF-I, IGF-II, and insulin. IGF-I and IGF-II share approximately 50% similarity with insulin at the amino acid level. Mouse IGF-I is synthesized as a 165 amino acid pre-pro-IGF-I, which includes the signal peptide, the mature protein, and the C-terminal E-peptide; the pro-IGFI possesses a proprotein convertase/furin cleavage site preceding the E-peptide. Pro-IGF-I is processed to the mature, active protein, and this procedure requires glucose regulating protein 94 (GRP94) that possesses chaperone activity towards IGF-I. Deletion of muscle GRP94 impairs muscle and body growth by inhibiting local production of IGF proteins. Seven binding proteins have been described (IGFBP-1 to 7). IGFBPs extend the half life and regulate the availability of IGF-I and IGF-II. It has been described that IGFBP3 is the main circulating binding protein for IGF's; in serum, approximately 75% of circulating IGF-I and IGF-II bind to IGFBP3 and the co-carrier acid labile subunit (ALS). IGF-I binds to three receptors, and the binding to IGFIR promotes cell proliferation, survival, differentiation, and migration. IGF-I is a key factor for muscle growth and repair. Inactivation of IGF-RI in skeletal muscle leads to 10-30% lower mass and delayed regeneration after injury.;
Caractéristiques
- Fournisseur
- BioLegend Europe BV
- Marque
- BIOLEGEND
- Référence fabricant
- 591402
- Référence distributeur
- 591402
- Vendu par
- 10 μg
- Quantité
- N/A
- Lieu de fabrication
- USA
- Lieu de stockage
- Pays-Bas ou USA
- Soumis à carboglace
- non
- Classement dans le catalogue fournisseur
- Recombinant Protein
- Certification
- RUO
- Type d’application
- bioassay
- Type de produit
- Recombinant Protein
- Température de conservation (°C)
- -20 ou -70 °C
- Température de transport
- Blue Ice
- Organisme cible
- Mouse
- Source biologique
- E. coli
- Seuil de coupure des masses moléculaires MWCO
- The 71 amino acid recombinant protein has a predicted molecular mass of approximately 7.8 kD. The DTT-reduced and non-reduced protein migrate at approximately 10 kD and 11 kD respectively by SDS-PAGE. Da
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration, please enter the lot number in our online tools.
- Pureté
- >95%, as determined by Coomassie stained SDS-PAGE. %
- Matière dangereuse
- Non
- Code douanier
- 38220000
- Classement NCBI
- 16000
- Nomenclature Nacres
- NA.77
- Nomenclature CEA
- SGP01
- Nomenclature IRSN
- 273
- Nomenclature INSERM
- NA.NA77
- Nomenclature CNRS
- NA77
- Nomenclature CHU
- 18.551
- Nomenclature DGOS
- LD11AOOO
- Reprise en cas d’erreur client
- non